Day: October 6, 2025

WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at https://investor.eagleus.com/events-presentations. About Eagle Pharmaceuticals, Inc. Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product...

SINGAPORE, Oct. 06, 2025 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Verde AgriTech Ltd. (TSX: NPK | OTCQX: VNPKF), please note: we updated the Appendix table to correct a presentation alignment. The column headings list the individual oxides in alphabetical order, followed by TREO and MREO; the data had appeared in the reverse order, which misaligned values with their headings. This update does not change the underlying assays or calculations. No changes were made to TREO, MREO, or individual rare earth element totals or interpretations; the update is limited to table alignment. The corrected Appendix follows. All other content remains unchanged. Continuous clay-hosted REE mineralised zone outlined. High-grade NdPr-rich samples return up to 8,930 ppm TREO and 2,182 ppm MREO. 22 samples return...

Carlsbad, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced a series of key leadership and governance changes aimed at strengthening its executive team, enhancing financial transparency, and supporting the Company’s next phase of strategic growth. Executive Appointments Effective October 2, 2025, Jerry (Jiawei) Wang was appointed as Co-Chief Executive Officer, and Koti Meka was appointed as Chief Financial Officer of Qualigen Therapeutics. Mr. Wang is the Global President and one of the original founding team members of Faraday Future and was deeply involved in strategic development from its inception starting from 2014, including successfully raising more than $3 billion funding, and led the successful initial public offering (IPO) in 2021. Mr. Meka is the CFO of Faraday...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Oct. 06, 2025 (GLOBE NEWSWIRE) — AlphaGen Intelligence Corp. (CSE: AIC | FSE: G4G) (“AlphaGen” or the “Company”) announces that it has entered into a debt settlement agreement with a certain creditor of the Company (the “Creditor”) pursuant to which the Company has agreed to issue to the Creditor, and the Creditor has agreed to accept, an aggregate of 52,812 common shares in the capital of the Company (each a “Settlement Share”), at a deemed value of $0.24 per Settlement Share, in full and final settlement of accrued and outstanding indebtedness in the aggregate amount of $12,675 (the “Debt Settlement Transaction”). All securities to be issued pursuant to the Debt Settlement Transactions will be subject...

Analyst Conference Call – 8:00 a.m. Pacific, Friday, November 7, 2025 BURNABY, British Columbia, Oct. 06, 2025 (GLOBE NEWSWIRE) — INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) will release its third quarter financial results on November 6, 2025.   The analyst conference call is scheduled for 8:00 am Pacific on Friday, November 7, 2025 and will feature a brief summary of financial results by Interfor management followed by a question and answer period with analysts.WHEN: Friday, November 7, 2025 at 8:00 am PTCALL DETAILS: 1-888-510-2154 (toll-free in North America)  or  Webcast URL: https://app.webinar.net/AZ0z6GjDG2e  Information related to Interfor’s third quarter financial results will be available at www.interfor.com/investorsRECORDING PLAYBACK: The conference call will also be recorded for...

MONTRÉAL, Oct. 06, 2025 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has redeemed all remaining outstanding US$166,289,000 aggregate principal amount of its 7.125% Senior Notes due 2026 (the “2026 Notes”) and US$83,711,000 aggregate principal amount of its outstanding 7.875% Senior Notes due 2027 (together with the 2026 Notes, the “Redemption Notes”), in each case effective October 4, 2025 and as set forth in the respective notices of redemption issued September 4, 2025. Payment of the redemption price and surrender of the Redemption Notes for redemption are being made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust Company. This press release does not constitute an offer to sell or buy or the solicitation of an offer to buy...

CALGARY, Alberta, Oct. 06, 2025 (GLOBE NEWSWIRE) — PrairieSky will release its Q3 2025 results on Monday, October 20, 2025 after markets close. The news release detailing PrairieSky’s Q3 2025 results will provide operating and financial information. Financial statements along with management’s discussion and analysis will be available on PrairieSky’s website at www.prairiesky.com and on SEDAR+ at www.sedarplus.com. A conference call to discuss the results will be held for the investment community on Tuesday, October 21, 2025 beginning at 6:30 am MT (8:30 am ET). To participate in the conference call, you are asked to register at the link provided below. Details regarding the call will be provided to you upon registration. Live call participant registration         URL:  https://register-conf.media-server.com/register/BIaba43cb9293745c9931d739ff67b042a Live...

CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company’s common stock (the “Inducement Awards”) to two new employees pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee’s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee’s continued employment on each vesting date). Each Inducement Award was approved by the Compensation Committee...

Company Introduces Integrated AI-Native Consulting and Implementation Model to Drive Scalable Growth through Professional Services, Licensing, and Subscription Revenues Vancouver, BC, Oct. 06, 2025 (GLOBE NEWSWIRE) — Fobi AI Inc. (OTCQB: FOBIF, TSXV: FOBI) (“Fobi” or the “Company”) announces the formal launch of Fobi AI 3.0, a new strategic and operational framework that aligns the Company’s consulting, licensing, and subscription businesses under a unified, AI-driven model. The launch of Fobi AI 3.0 represents an important evolution in the Company’s business model and operations. Fobi AI 3.0 defines the Company’s framework as an AI-native professional services and implementation platform that unites strategic advisory expertise with the practical deployment of its proprietary AI, mobile wallet, and data intelligence technologies....